Log in

NASDAQ:ESPREsperion Therapeutics Stock Price, Forecast & News

$33.69
+0.21 (+0.63 %)
(As of 08/12/2020 04:00 PM ET)
Add
Compare
Today's Range
$33.34
Now: $33.69
$34.44
50-Day Range
$33.48
MA: $45.11
$52.71
52-Week Range
$24.82
Now: $33.69
$76.98
Volume907,619 shs
Average Volume763,097 shs
Market Capitalization$930.42 million
P/E RatioN/A
Dividend YieldN/A
Beta2
Esperion Therapeutics, Inc., a lipid management company, focuses on developing and commercializing oral therapies for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its lead product candidate is bempedoic acid/ezetimibe combination pill, a non-statin, orally available, LDL-C lowering therapy for patients with hypercholesterolemia and with atherosclerotic cardiovascular disease, and/or heterozygous familial hypercholesterolemia that is in Phase III long-term safety and tolerability study. Esperion Therapeutics, Inc. was founded in 2008 and is headquartered in Ann Arbor, Michigan.
Read More
Esperion Therapeutics logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.3Community Rank: 2.8Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.22 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ESPR
CUSIPN/A
Phone734-887-3903

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$148.36 million
Book Value$0.73 per share

Profitability

Net Income$-97,170,000.00
Net Margins-5,492.02%

Miscellaneous

Employees76
Market Cap$930.42 million
Next Earnings Date11/4/2020 (Estimated)
OptionableOptionable
$33.69
+0.21 (+0.63 %)
(As of 08/12/2020 04:00 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive ESPR News and Ratings via Email

Sign-up to receive the latest news and ratings for ESPR and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Esperion Therapeutics (NASDAQ:ESPR) Frequently Asked Questions

How has Esperion Therapeutics' stock been impacted by Coronavirus?

Esperion Therapeutics' stock was trading at $42.93 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, ESPR stock has decreased by 21.5% and is now trading at $33.69.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of Esperion Therapeutics?

13 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Esperion Therapeutics in the last year. There are currently 5 hold ratings and 8 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Esperion Therapeutics
.

When is Esperion Therapeutics' next earnings date?

Esperion Therapeutics is scheduled to release its next quarterly earnings announcement on Wednesday, November 4th 2020.
View our earnings forecast for Esperion Therapeutics
.

How were Esperion Therapeutics' earnings last quarter?

Esperion Therapeutics Inc (NASDAQ:ESPR) released its quarterly earnings results on Monday, August, 10th. The biopharmaceutical company reported $4.32 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $2.13 by $2.19. The biopharmaceutical company had revenue of $212.24 million for the quarter, compared to analyst estimates of $147.97 million. Esperion Therapeutics had a negative return on equity of 627.38% and a negative net margin of 5,492.02%. The business's quarterly revenue was up 21557.1% on a year-over-year basis. During the same quarter last year, the business earned ($2.01) EPS.
View Esperion Therapeutics' earnings history
.

What price target have analysts set for ESPR?

13 brokers have issued 1-year price targets for Esperion Therapeutics' shares. Their forecasts range from $42.00 to $191.00. On average, they anticipate Esperion Therapeutics' stock price to reach $78.54 in the next twelve months. This suggests a possible upside of 133.1% from the stock's current price.
View analysts' price targets for Esperion Therapeutics
.

What are Wall Street analysts saying about Esperion Therapeutics stock?

Here are some recent quotes from research analysts about Esperion Therapeutics stock:
  • 1. According to Zacks Investment Research, "Esperion announced encouraging fourth quarter results, wherein earnings and revenues beat estimates. The company received approval for its two drugs, Nexletol and Nexlizet, in February 2020, which was a major boost. The company plans to launch Nexletol in March and Nexlizet in July. Regulatory applications seeking approval for these drugs are under review in Europe. Both candidates have achieved significant reduction in elevated LDL-C levels in hypercholesterolemia patients. The targeted area represents a significant opportunity. Shares have outperformed the industry in the past year. However, Esperion is heavily dependent on the successful commercialization of Nexletol and Nexlizet. The company will likely face stiff competition as its drugs target a crowded market. Esperion also has no other pipeline candidates." (3/26/2020)
  • 2. Stifel Nicolaus analysts commented, "We are reiterating our Buy rating and lowering our target price to $70 which reflects a more conservative pre-CVOT BPA/combo sales ramp and higher SG&A assumptions. Even with our more conservative forecasts, we believe ESPR is undervalued at these levels (EV of ~$700 million) as we think the stock continues to reflect investor skepticism on the commercial opportunity for BPA/ combo and the company’s cash runway. We view BPA/combo as a clinically de-risked asset with two upcoming and believe BPA’s CVOT design portends a high probability of success. Further, our recent KOL checks have been consistent with our past discussions (see deep dive) in validating what we believe is a meaningful commercial opportunity for BPA/combo in the statin intolerant population." (9/17/2019)
  • 3. Northland Securities analysts commented, "We are now modeling $0.69 in non-GAAP EPS on $97.8 million in revenue for FY/19." (8/29/2019)

Has Esperion Therapeutics been receiving favorable news coverage?

News headlines about ESPR stock have been trending extremely negative on Thursday, InfoTrie Sentiment reports. InfoTrie ranks the sentiment of media coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Esperion Therapeutics earned a media sentiment score of -4.1 on InfoTrie's scale. They also assigned news stories about the biopharmaceutical company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an impact on the company's share price in the immediate future.
View the latest news about Esperion Therapeutics
.

Who are some of Esperion Therapeutics' key competitors?

What other stocks do shareholders of Esperion Therapeutics own?

Who are Esperion Therapeutics' key executives?

Esperion Therapeutics' management team includes the following people:
  • Mr. Timothy M. Mayleben M.B.A., Pres, CEO & Director (Age 58)
  • Dr. Narendra D. Lalwani, Exec. VP of R&D (Age 66)
  • Mr. Richard B. Bartram, CFO & Corp. Sec. (Age 37)
  • Mr. Alexander Duke Schwartz, Sr. Director of Investor Relations
  • Ms. Marianne Andreach, Sr. VP

What is Esperion Therapeutics' stock symbol?

Esperion Therapeutics trades on the NASDAQ under the ticker symbol "ESPR."

Who are Esperion Therapeutics' major shareholders?

Esperion Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Wasatch Advisors Inc. (4.51%), Platinum Investment Management Ltd. (3.08%), Rhenman & Partners Asset Management AB (1.54%), Goldman Sachs Group Inc. (1.13%), Barclays PLC (0.67%) and Candriam Luxembourg S.C.A. (0.42%). Company insiders that own Esperion Therapeutics stock include Boxer Capital, Llc, Nicole Vitullo, Richard Bartram, Roger S Newton, Target N V Biotech and Timothy M Mayleben.
View institutional ownership trends for Esperion Therapeutics
.

Which major investors are selling Esperion Therapeutics stock?

ESPR stock was sold by a variety of institutional investors in the last quarter, including Rhenman & Partners Asset Management AB, Candriam Luxembourg S.C.A., Nicholas Investment Partners LP, SG Americas Securities LLC, Ensign Peak Advisors Inc, Raymond James Financial Services Advisors Inc., Russell Investments Group Ltd., and PNC Financial Services Group Inc..
View insider buying and selling activity for Esperion Therapeutics
.

Which major investors are buying Esperion Therapeutics stock?

ESPR stock was bought by a variety of institutional investors in the last quarter, including Wasatch Advisors Inc., Goldman Sachs Group Inc., Platinum Investment Management Ltd., Mutual of America Capital Management LLC, Rafferty Asset Management LLC, UBS Group AG, Trexquant Investment LP, and Moody Aldrich Partners LLC. Company insiders that have bought Esperion Therapeutics stock in the last two years include Target N V Biotech, and Timothy M Mayleben.
View insider buying and selling activity for Esperion Therapeutics
.

How do I buy shares of Esperion Therapeutics?

Shares of ESPR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Esperion Therapeutics' stock price today?

One share of ESPR stock can currently be purchased for approximately $33.69.

How big of a company is Esperion Therapeutics?

Esperion Therapeutics has a market capitalization of $930.42 million and generates $148.36 million in revenue each year. The biopharmaceutical company earns $-97,170,000.00 in net income (profit) each year or ($3.59) on an earnings per share basis. Esperion Therapeutics employs 76 workers across the globe.

What is Esperion Therapeutics' official website?

The official website for Esperion Therapeutics is www.esperion.com.

How can I contact Esperion Therapeutics?

Esperion Therapeutics' mailing address is 3891 RANCHERO DRIVE SUITE 150, ANN ARBOR MI, 48108. The biopharmaceutical company can be reached via phone at 734-887-3903 or via email at [email protected]

This page was last updated on 8/13/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.